Emergent BioSolutions (LTS:0IGA) Other Long-Term Liabilities : $35.4 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Emergent BioSolutions Other Long-Term Liabilities?

Emergent BioSolutions's other long-term liabilities for the quarter that ended in Mar. 2025 was $35.4 Mil.

Emergent BioSolutions's quarterly other long-term liabilities increased from Sep. 2024 ($35.8 Mil) to Dec. 2024 ($39.1 Mil) but then declined from Dec. 2024 ($39.1 Mil) to Mar. 2025 ($35.4 Mil).

Emergent BioSolutions's annual other long-term liabilities declined from Dec. 2022 ($41.5 Mil) to Dec. 2023 ($28.9 Mil) but then increased from Dec. 2023 ($28.9 Mil) to Dec. 2024 ($39.1 Mil).

Emergent BioSolutions Other Long-Term Liabilities Historical Data

The historical data trend for Emergent BioSolutions's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Other Long-Term Liabilities Chart

Emergent BioSolutions Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

102.00

69.50

41.50

28.90

39.10

Emergent BioSolutions Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial															28.00	25.70	35.80	39.10	35.40

Emergent BioSolutions Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Emergent BioSolutions Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (LTS:0IGA) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

EBS:USA ER4:Germany

Address

300 Professional Drive, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Headlines

No Headlines